tbuckley/cabot-search huggingface dataset:
EMOTIONAL STATES AND THE SUPRARENAL SECRETION
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impaired pressor reactivity in cirrhosis: Evidence for a peripheral vascular defect
Authors: A MacGilchrist
Journal: Hepatology (1991)

The blood pressure responses to intravenous infusions of norepinephrine and angiotensin II, sympathetic and nonsympathetic vasoconstricting agents, respectively, were measured in 20 patients with cirrhosis (10 Child-Pugh grade A and 10 Child-Pugh grades B or C) and in 20 healthy subjects. The log PD20 (dose of agonist required to raise blood pressure by 20 mm Hg) for norepinephrine was 4.78 ± 0.36 (mean ± S.D.) in patients with severe cirrhosis and 4.36 ± 0.37 in controls, p < 0.01. Log PD20 for angiotensin II was 3.16 ± 1.06 in patients with severe cirrhosis and 1.97 ± 0.74 in controls, p < 0.01. Cardiovascular responses to selective sympathetic agonists were measured in 10 other cirrhotic patients (all Child-Pugh grades B or C) and in 10 healthy controls. Log PD20s for phenylephrine, an α-1 adrenoceptor agonist, and for alphamethylnorepinephrine; an α-2 adrenoceptor agonist, were increased in cirrhosis (phenylephrine = 5.35 ± 0.49 vs. 4.95 ± 0.35, p < 0.05; alphamethylnorepinephrine = 4.05 ± 0.26 vs. 3.44 ± 0.55, p < 0.001). In contrast, log CD20 (dose of agonist required to raise the heart rate by 20 beats/min) for isoproterenol, a β-adrenoceptor agonist, was similar in cirrhotic patients and controls (2.81 ± 0.38 vs. 2.94 ± 0.45, p = 0.49). These studies demonstrate that pressor reactivity to both sympathetic and nonsympathetic agonists is impaired in severe cirrhosis, that the impaired sympathetic responses are not caused by generalized sympathetic desensitization and that the site common to the four agonists with impaired responses is the peripheral vascular smooth muscle. (HEPATOLOGY 1991;13:689–694.)
P134 (0156) INDUCTION THERAPY WITH EVEROLIMUS IN COMBINATION WITH DHAP (DEXAMETHASONE, HIGH‐DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO‐CONTROLLED PHASE I/II TRIAL (HD‐R3I)
Journal: HemaSphere (2018)
THE DIAGNOSTIC VALUE OF LUMBAR PUNCTURE.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PERIL TO THE COMMUNITY OF ALCOHOLIC MANIA.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluating psychiatric treatment
Authors: E. T. Shapiro
Journal: JAMA (1978)

PSYCHIATRISTS, like everyone else, win some and lose some.<sup>1(pp722-756)</sup>The inability of a psychiatrist to cure or to alleviate a patient's illness may reflect the psychiatrist's limitations with a refractory illness, or it may reflect some difficulty the patient is having in perceiving the benefit of therapy. Occasionally, failure is due to the psychiatrist's lack of skill or to the interference of the psychiatrist's own problems in the therapy.<sup>2</sup>More often, failure is due to obstacles inherent in the nature of psychotherapy as a treatment technique. In many of these instances, one psychiatrist may succeed where a colleague has failed, since a patient who gives a detailed description of his disappointment with his former psychiatrist provides his new physician with valuable information. The patient or his family, angered or disappointed by failure, may ask our opinion about the psychotherapy. We should be able to distinguish proper psychiatric treatment
The American Society of Clinical Oncology and American Society of Hematology Recommended Criteria for the Performance of Bone Marrow Transplantation.
Journal: Journal of Clinical Oncology (1990)

Both autologous and allogeneic bone marrow transplantation involve the management of severely immunosuppressed patients for extended periods of time. Both the extent and the duration of the immunosuppression and certain unique technical issues (eg, cryopreservation and the management of graft v host disease) require special preparation and commitment in any organization undertaking bone marrow transplantation. Participation in clinical trials is important. The following criteria are those minimally necessary for the safe and successful performance of the procedure.
Fluorouracil
Authors: Edward S. Greenwald
Journal: JAMA (1975)

<h3>To the Editor.—</h3> For the past seven years I have been using fluorouracil to treat patients with metastatic cancer. In the last four years, I have given up the use of loading doses and administered 15 mg/kg intravenously weekly to almost all patients. Although I have not kept precise records of all side effects, I have noted that many patients complain of dry skin and mild nosebleeds in the absence of thrombocytopenia. To my surprise, I recently learned that neither of these side effects has been reported to Roche Laboratories, the distributor of fluorouracil. I then reviewed my records of all patients recently receiving fluorouracil alone without other chemotherapeutic agents, and was able to find seven who complained of moderate to severe dryness of the skin, most marked on the palms of the hands, and the soles of the feet. In four of these patients, the dryness was severe and
From antibiotics to ibrutinib: An array of treatment modalities
Authors: Catherine Thieblemont
Journal: HemaSphere (2018)

APHP, Hôpital Saint-Louis, Diderot University, Sorbonne Paris Cité, Paris, France This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
Book Review Lectures on Peace and War Orthopedic Surgery . Selected from the instructional courses presented at the eleventh annual assembly of the American Academy of Orthopaedic Surgeons, Chicago, January 17, 18, 19, 20 and 21, 1943. Edited by James E. M. Thomson, M.D. 4°, cloth, 322 pp., illustrated. Ann Arbor, Michigan: Edwards Brothers, Incorporated, 1943. $4.00.
Journal: New England Journal of Medicine (1944)
Pasteur: The History of a Mind.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Counterfeit Norco Poses New Danger
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply
Authors: Thomas Gruenberger, Birgit Gruenberger
Journal: Journal of Clinical Oncology (2008)

We thank Dr Nasti and his colleagues for their interest in our study, 1 and welcome their ideas to improve outcome in patients with resectable liver metastases from colorectal cancer.They explain some concerns regarding the use of neoadjuvant chemotherapy in patients who may not benefit from this approach, and favor an alternative treatment schedule including positron emission tomography (PET) to identify responders after a single chemotherapy cycle.The authors outline in their reply that patients with stable or progressive disease while receiving chemotherapy lack the potential of a surgical intervention.We would like to emphasize that achieving stable disease while receiving chemotherapy is still believed to be an attainment and improves outcome parameters in these patients.However, it is correct that the identification of progressive disease is important, but in contrast to the opinion of the authors, to our knowledge these patients will not benefit from a surgical intervention even if they can stil undergo resection, and should therefore undergo second-line chemotherapy instead. 2,3 The identification of predictors for response is an important issue and the use of a [18F]fluorodeoxyglucose-PET for an early evaluation is certainly one of the methods currently under investigation.It seems specifically interesting in patients receiving antiangiogenic drug-containing regimens because that a certain percentage of the liver metastases in these patients seem to respond to treatment without fulfilling the Response Evaluation Criteria in Solid Tumors criteria of response.This is demonstrated in a higher percentage of pathologic tumor necrosis, 4 an increase in pathologic complete response rates, 1 a higher PET response compared with computed tomography response, 5 and a decrease in contrast enhancement. 6 To date, we have not recognized a different response pattern depending on tumor size, demonstrated in our article, where a significant tumor size reduction in a patient with a large metastasis is illustrated.In summary, we support the necessity to identify responding patients during neoadjuvant treatment with early predictors and thereby increase the optimal sequence of chemotherapy and surgery.
07.15 New mutated peptidylarginine deiminase from porphyromonas gingivalis a target in early ra citrullinates major ra-autoantigens
Authors: Madeleine Jenning, Bianka Marklein, Jimmy Ytterberg, Gerd R Burmester, Karl Skriner
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Previous reports showed that peptidylarginine deiminase (PPAD) form <i>Porphyromonas gingivalis (P.g.)</i> is not able to citrullinate proteins internally. New mutated PPAD (mPPAD) from <i>P.g.</i> involved in periodontal disease (PD) cloned out of <i>P.g.</i> strain was characterised and analysed for its reactivity in sera from patients with systemic autoimmune diseases. <h3>Methods</h3> Recombinant mutated PPAD from <i>P.g. mPPAD</i> mutations and citrullination sites were analysed by DNA sequencing and/or protein mass spectrometry. Autocitrullination activity it´s enzymatic-activity and human autoantigen protein citrullination was investigated by 2D-Elektrophoresis, MS, immunoblot analysis and ELISA. Furthermore we tested anti-mPPAD/cit-mPPAD with human sera (n=93) from early RA before and after onset of RA (n=30), established RA (n=32), SLE (n=16) and healthy blood donors (n=15) in ELISA assays. In RA mouse model collagen antibody-induced arthritis (CAIA), mPPAD-containing vesicles from <i>P.g.</i> were injected by intraperitoneal injection (IP). <h3>Results</h3> Recombinant mPPAD lacks 43 amino acids at the N-terminus and exhibits so far two new amino acid mutations (aminoacid position 73 (F&gt;L) and 447 (E&gt;V). We were able to demonstrate, mPPAD is enzymatically active over a huge pH-range (3-10) and autocitrullinates at amino acid position 63 the arginine to citrulline. Moreover mPPAd citrullinates major autoantigens in RA (Fibrinogen, Vimentin and hnRNP-A2/B1) which are detectable by RA patient sera and specific anti-citrulline monoclonal antibodies. mPPAD citrullinates HeLa-protein extracts and these specific citrullinated proteins are recognised by RA patient sera. Anti-citrullinated mPPAD antibodies were detected in 41% (n=32) of patients with RA but not in SLE (n=16) and control sera (n=15). In a RA follow-up study (n=30), we detected nearly similar antibody-sensitivities for citrullinated mPPAD before and after onset of RA (13/20%). Only a minority (7%) of RA patients show higher mPPAD antibody levels after RA diagnosis. In the CAIA RA mouse model mPPAD containing <i>P.g.</i> vesicles when injected IP showed a TLR2-dependent protective anti-inflammatory effect like <i>P.g.</i> LPS and Lipomannan. <h3>Conclusions</h3> Pg. infection and RA disease diagnosis occurs at different time points and Pg. infection induces a TLR2-dependent protective anti-inflammatory effect.We show the first time that mPPAD can citrullinate major human autoantigens internally and their immunologically and diagnostic relevance in RA.
Rhinoviraemia
Authors: G. E. D. Urquhart, E. J. Stott
Journal: BMJ (1970)

Rhinoviruses have been isolated from the serum of two infants at necropsy. Failure to isolate viruses from ten other sera from infants who yielded rhinoviruses from their respiratory tracts suggests that true rhinoviraemia occurs rarely, and is infrequently associated with rhinovirus infections, both clinical and subclinical, and death. It is suggested that this is the first report of isolations of human rhinoviruses from the blood.
P3.03-06 Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes
Authors: T. Tokar, C. Pastrello, V. Ramnarine, C. Zhu, K. Craddock, L. Pikor, E. Vucic, S. Vary, F. Shepherd, M. Tsao, W. Lam, I. Jurisica
Journal: Journal of Thoracic Oncology (2018)
Manual of Personal Hygiene. Proper Living on a Physiologic Basis.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OS2.8 Survival gain and immune response in glioblastoma patients treated with dendritic cell immunotherapy before and during adjuvant temozolomide
Authors: S. Pellegatta, M. Eoli, E. Anghileri, S. Frigerio, V. Cuccarini, C. Antozzi, B. Pollo, S. Pessina, M. Bruzzone, G. Finocchiaro
Journal: Neuro-Oncology (2016)
THE USE OF DRUGS IN NEUROLOGY AND PSYCHIATRY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In vivo evaluation of a hollow fiber liver assist device
Authors: H JAUREGUI
Journal: Hepatology (1995)

Orthotopic liver transplantation is the only effective form of therapy currently available for patients with fulminant hepatic failure (FHF). The use of an extracorporeal (EC) liver assist device (LAD) may result in improved presurgical clinical management. Alternatively, patients treated with LADs could avoid the transplantation procedure if they are able to regenerate a critical mass of hepatocytes that will sustain functional viability. In this study, the efficacy of a prototype hollow fiber LAD seeded with rabbit hepatocytes was assessed in vivo by the use of two different animal models: (1) normal rabbits injected with diazepam or lidocaine, and (2) a galactosamine (Gal)-intoxicated rabbit model of FHF. The EC LAD clearly decreased the blood levels of the two drugs and significantly generated diazepam and lidocaine metabolites indicating the maintenance of active P450 forms in the cellular component of the devices. A 6-hour EC treatment significantly increased the survival time and delayed the onset of hepatic encephalopathy (HE) in the Gal-intoxicated rabbits. Histological evaluations of postmortem livers showed greater hepatocyte regenerative activity in the animals treated with hepatocyte-seeded LADs than in the two control groups, e.g., rabbits not treated or treated with unseeded devices. These findings support the concept that a microporous hollow fiber LAD seeded with rabbit hepatocytes is able to sustain drug detoxification in vivo as well as to modify the course of FHF in a well-characterized animal model. (HEPATOLOGY 1995;21:460–469.)
The Removal of Mercury from Dental-Operatory Wastewater by Polymer Treatment
Authors: Ernest D. Pederson, Mark E. Stone, Victor G. Ovsey
Journal: Environmental Health Perspectives (1999)

The mercury (Hg) content of dental-operatory wastewater has become an issue in many localities, and Hg removal is rapidly becoming a matter of concern for all dental clinics. This preliminary study tested the efficacy of polymers for the removal of Hg contaminants from the dental-unit wastewater stream. Two commercially available polymers were used to treat dental-operatory wastewater. Used separately, each polymer removed from 74.9% to 88.4% of the Hg from dental-wastewater supernatant. The polymers used in combination, within the recommended pH range, removed up to 99.9% of the total Hg from dental-wastewater supernatant. The estimated optimal concentration of the two polymers is approximately 2.33 ml of each per liter of waste, and more than 90% of the Hg may be removed with 0.13 ml/l. Results indicate that a combination of the two polymers may sufficiently reduce Hg levels to allow discharge of clarified supernatants into public sewer systems.